These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

575 related items for PubMed ID: 15126694

  • 1. Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis.
    Wyttenbach A.
    J Mol Neurosci; 2004; 23(1-2):69-96. PubMed ID: 15126694
    [Abstract] [Full Text] [Related]

  • 2. [Molecular biology of polyglutamine diseases].
    Owecki M, Kozubski W.
    Postepy Hig Med Dosw; 2002; 56(6):779-88. PubMed ID: 12661407
    [Abstract] [Full Text] [Related]

  • 3. [The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
    Bogomazova AN, Eremeev AV, Pozmogova GE, Lagarkova MA.
    Mol Biol (Mosk); 2019; 53(6):954-967. PubMed ID: 31876275
    [Abstract] [Full Text] [Related]

  • 4. Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein.
    Fu L, Gao YS, Sztul E.
    Neurobiol Dis; 2005 Dec; 20(3):656-65. PubMed ID: 15964198
    [Abstract] [Full Text] [Related]

  • 5. Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.
    Reis SD, Pinho BR, Oliveira JMA.
    Mol Neurobiol; 2017 Oct; 54(8):5829-5854. PubMed ID: 27660272
    [Abstract] [Full Text] [Related]

  • 6. Role of molecular chaperones in neurodegenerative disorders.
    Meriin AB, Sherman MY.
    Int J Hyperthermia; 2005 Aug; 21(5):403-19. PubMed ID: 16048838
    [Abstract] [Full Text] [Related]

  • 7. Polyglutamine disease proteins: Commonalities and differences in interaction profiles and pathological effects.
    Bonsor M, Ammar O, Schnoegl S, Wanker EE, Silva Ramos E.
    Proteomics; 2024 Jun; 24(12-13):e2300114. PubMed ID: 38615323
    [Abstract] [Full Text] [Related]

  • 8. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation.
    Schaffar G, Breuer P, Boteva R, Behrends C, Tzvetkov N, Strippel N, Sakahira H, Siegers K, Hayer-Hartl M, Hartl FU.
    Mol Cell; 2004 Jul 02; 15(1):95-105. PubMed ID: 15225551
    [Abstract] [Full Text] [Related]

  • 9. Heat shock proteins and neuroprotection.
    Trivedi S.
    Recent Pat DNA Gene Seq; 2007 Jul 02; 1(2):134-7. PubMed ID: 19075927
    [Abstract] [Full Text] [Related]

  • 10. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
    Nagai Y, Popiel HA.
    Curr Pharm Des; 2008 Jul 02; 14(30):3267-79. PubMed ID: 19075705
    [Abstract] [Full Text] [Related]

  • 11.
    Lo DC, Hughes RE, La Spada AR, Weydt P, Pineda VV.
    ; 2011 Jul 02. PubMed ID: 21882412
    [Abstract] [Full Text] [Related]

  • 12. [The advances in research on phosphorylation of polyglutamine disease].
    Zhou YF, Jiang H, Tang JG, Tang BS.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug 02; 25(4):414-7. PubMed ID: 18683139
    [Abstract] [Full Text] [Related]

  • 13. Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration.
    Tenchov R, Sasso JM, Zhou QA.
    ACS Chem Neurosci; 2024 Aug 07; 15(15):2665-2694. PubMed ID: 38996083
    [Abstract] [Full Text] [Related]

  • 14. Protective effect of chaperones on polyglutamine diseases.
    Kobayashi Y, Sobue G.
    Brain Res Bull; 2024 Aug 07; 56(3-4):165-8. PubMed ID: 11719246
    [Abstract] [Full Text] [Related]

  • 15. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders.
    Ross CA.
    Neuron; 2002 Aug 29; 35(5):819-22. PubMed ID: 12372277
    [Abstract] [Full Text] [Related]

  • 16. Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation.
    Minakawa EN, Popiel HA, Tada M, Takahashi T, Yamane H, Saitoh Y, Takahashi Y, Ozawa D, Takeda A, Takeuchi T, Okamoto Y, Yamamoto K, Suzuki M, Fujita H, Ito C, Yagihara H, Saito Y, Watase K, Adachi H, Katsuno M, Mochizuki H, Shiraki K, Sobue G, Toda T, Wada K, Onodera O, Nagai Y.
    Brain; 2020 Jun 01; 143(6):1811-1825. PubMed ID: 32436573
    [Abstract] [Full Text] [Related]

  • 17. The role of heat shock proteins as chaperones on several human diseases.
    Mellati AA.
    Saudi Med J; 2006 Sep 01; 27(9):1302-5. PubMed ID: 16951762
    [Abstract] [Full Text] [Related]

  • 18. Current understanding on the pathogenesis of polyglutamine diseases.
    He XH, Lin F, Qin ZH.
    Neurosci Bull; 2010 Jun 01; 26(3):247-56. PubMed ID: 20502504
    [Abstract] [Full Text] [Related]

  • 19. The Expanding Clinical Universe of Polyglutamine Disease.
    Huang S, Zhu S, Li XJ, Li S.
    Neuroscientist; 2019 Oct 01; 25(5):512-520. PubMed ID: 30614396
    [Abstract] [Full Text] [Related]

  • 20. The small heat shock proteins, especially HspB4 and HspB5 are promising protectants in neurodegenerative diseases.
    Zhu Z, Reiser G.
    Neurochem Int; 2018 May 01; 115():69-79. PubMed ID: 29425965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.